Gabe S Sonke

Gabe S Sonke

UNVERIFIED PROFILE

Are you Gabe S Sonke?   Register this Author

Register author
Gabe S Sonke

Gabe S Sonke

Publications by authors named "Gabe S Sonke"

Are you Gabe S Sonke?   Register this Author

77Publications

2021Reads

16Profile Views

Validation of the online prediction model CancerMath in the Dutch breast cancer population.

Breast Cancer Res Treat 2019 Dec 30;178(3):665-681. Epub 2019 Aug 30.

Department of Research, Netherlands Comprehensive Cancer Organisation, P.O. Box 19079, 3501 DB, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05399-2DOI Listing
December 2019

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

N Engl J Med 2019 Dec 11. Epub 2019 Dec 11.

From the David Geffen School of Medicine at UCLA, Los Angeles (D.J.S.); Multidisciplinary Breast Center, Universitair Ziekenhuis Leuven, Leuven (P.N.), and Centre Hospitalier Universitaire Liège and Liege University, Liege (G.J.) - all in Belgium; the British Columbia Cancer Agency, Vancouver, Canada (S.C.); University Hospital Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, and Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), and the Practice for Hematology and Internal Oncology, Velbert (A.N.) - all in Germany; Istituto Nazionale Tumori Fondazione G. Pascale, Naples (M.D.L.), and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (G.V.B.) - both in Italy; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); New York University Langone Health, New York (F.J.E.); Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.), and Hospital Universitario Virgen Macarena, Department of Medicine, Universidad de Sevilla, Seville (L.D.C.-M.) - both in Spain; Netherlands Cancer Institute-Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Highlands Oncology Group, Fayetteville, AR (J.T.B.); Institut Régional du Cancer, Strasbourg, France (X.P.); Novartis Pharmaceuticals, East Hanover, NJ (M.S., A.C., K.R.-L.); and Novartis Pharma, Basel, Switzerland (Y.W., T.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911149DOI Listing
December 2019

Adherence to and satisfaction with low-intensity physical activity and supervised moderate-high intensity exercise during chemotherapy for breast cancer.

Support Care Cancer 2019 Aug 8. Epub 2019 Aug 8.

Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-05019-1DOI Listing
August 2019

[Cancer treatment; there are options].

Ned Tijdschr Geneeskd 2019 May 31;163. Epub 2019 May 31.

UMC Utrecht, divisie Beeld en Kanker, Utrecht.

View Article

Download full-text PDF

Source
May 2019

Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study.

Int J Cancer 2019 01 28;144(2):263-272. Epub 2018 Nov 28.

Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.31914
Publisher Site
http://dx.doi.org/10.1002/ijc.31914DOI Listing
January 2019

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

N Engl J Med 2018 12 21;379(26):2495-2505. Epub 2018 Oct 21.

From the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica, Rome (G.S.) - both in Italy; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (B.-G.K.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (A. Oaknin), and M.D. Anderson Cancer Centre Madrid, Madrid (A.G.-M.) - both in Spain; University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, Australia (M.F.); St. Petersburg City Oncology Dispensary, St. Petersburg, Russia (A. Lisyanskaya); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris (A.F., A. Leary), Institut Bergonié, Comprehensive Cancer Center, Bordeaux (A.F.), and Gustave-Roussy Cancer Campus, Villejuif (A. Leary) - all in France; the Netherlands Cancer Institute, Amsterdam (G.S.S.); Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (C.G.), the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London (S.B.), and AstraZeneca, Cambridge (R.B.) - all in the United Kingdom; Princess Margaret Cancer Centre, Toronto (A. Oza); Memorial Sloan Kettering Cancer Center, New York (C.A.); Froedtert and the Medical College of Wisconsin, Milwaukee (W.B.); Women and Infants Hospital, Providence, RI (C.M., P.D.); Dana-Farber Cancer Institute, Boston (J.L.); and AstraZeneca, Gaithersburg, MD (E.S.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1810858
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1810858DOI Listing
December 2018

[Critical doctors and cognitive bias].

Ned Tijdschr Geneeskd 2018 12 5;162. Epub 2018 Dec 5.

Gold Coast University Hospital, dep. Emergency Medicine, Southport, Australië.

View Article

Download full-text PDF

Source
December 2018

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

J Clin Oncol 2018 08 3;36(24):2465-2472. Epub 2018 Jun 3.

Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9909
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9909DOI Listing
August 2018

Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy.

Eur J Health Econ 2018 Jul 30;19(6):893-904. Epub 2017 Oct 30.

Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10198-017-0936-0DOI Listing
July 2018

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

N Engl J Med 2018 04;378(14):1363-1364

Netherlands Cancer Institute, Amsterdam, the Netherlands

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1802033DOI Listing
April 2018

Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery.

Gynecol Oncol 2018 01 10;148(1):56-61. Epub 2017 Nov 10.

Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.11.009DOI Listing
January 2018

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

N Engl J Med 2018 01;378(3):230-240

From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.), Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K., G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K., N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M., G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center, Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.), Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H., A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen (H.J.A.), and the Department of Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - all in the Netherlands; and the Department of Surgery, Aarhus University Hospital, Aarhus, Denmark (V.J.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1708618DOI Listing
January 2018

Surveillance of Dutch Patients With Li-Fraumeni Syndrome: The LiFe-Guard Study.

JAMA Oncol 2017 12;3(12):1733-1734

Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.1346DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824278PMC
December 2017

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Drugs 2017 Aug;77(12):1313-1336

Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-017-0774-5DOI Listing
August 2017

MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.

Breast Cancer Res Treat 2017 Jul 21;164(1):99-106. Epub 2017 Apr 21.

Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4254-0DOI Listing
July 2017

Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review.

Crit Rev Oncol Hematol 2017 Apr 17;112:198-207. Epub 2017 Feb 17.

Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Department of Health Technology and Services Research, MB-HTSR, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.02.014DOI Listing
April 2017

Doctors' reports about palliative systemic treatment: A medical record study.

Palliat Med 2017 03 19;31(3):239-246. Epub 2016 Aug 19.

1 Department of Registry and Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0269216316661685DOI Listing
March 2017

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

J Clin Oncol 2016 12 28;34(36):4354-4361. Epub 2016 Oct 28.

Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke, Daphne de Jong, Efraim H. Rosenberg, Serena Marchetti, Dick Pluim, Erik van Werkhoven, Jos H. Beijnen, and Jan H.M. Schellens, The Netherlands Cancer Institute, Amsterdam; Jos H. Beijnen and Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands; and Shelonitda Rose, Mark A. Lee, and Tomoko Freshwater, Merck, Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.5942DOI Listing
December 2016

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2016 11 7;375(18):1738-1748. Epub 2016 Oct 7.

From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609709DOI Listing
November 2016

Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

Breast Cancer Res Treat 2016 09;159(2):393

Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3941-6DOI Listing
September 2016

Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer?

Psychooncology 2016 08 17;25(8):964-70. Epub 2015 Aug 17.

Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.3936DOI Listing
August 2016

The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

Breast Cancer Res Treat 2016 07 29;158(2):361-71. Epub 2016 Jun 29.

Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3878-9DOI Listing
July 2016

Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer.

J Clin Oncol 2016 06 14;34(18):2107-14. Epub 2016 Mar 14.

Kim C. Aalders, Emily L. Postma, and Thijs van Dalen, Diakonessenhuis; Margriet van der Heiden-van der Loo and Sabine Siesling, Netherlands Comprehensive Cancer Organization; Paul J. van Diest, University Medical Center Utrecht, Utrecht; Luc J. Strobbe, Canisius Wilhelmina Hospital, Nijmegen; Gabe S. Sonke, Netherlands Cancer Institute, Amsterdam; Liesbeth J. Boersma, University Hospital Maastricht, Maastricht; and Sabine Siesling, University of Twente, Enschede, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.3536DOI Listing
June 2016

Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval.

PLoS One 2015 10;10(4):e0120832. Epub 2015 Apr 10.

Department of Health Technology and Services Research, MIRA Institute of Biomedical Technology and Technical Medicine, Twente University, Enschede, The Netherlands; Department of Registration and Research, Comprehensive Cancer Centre the Netherlands (IKNL), Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120832PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393268PMC
April 2016

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Lancet Oncol 2015 Dec 23;16(16):1639-50. Epub 2015 Oct 23.

Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147020451500286
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(15)00286-7DOI Listing
December 2015

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?

Cureus 2015 Dec 24;7(12):e433. Epub 2015 Dec 24.

Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727954PMC
December 2015

Bereaved relatives' experiences during the incurable phase of cancer: a qualitative interview study.

BMJ Open 2015 Nov 25;5(11):e009009. Epub 2015 Nov 25.

Department of Registry & Research, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2015-009009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663398PMC
November 2015

Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients.

Breast Cancer Res Treat 2015 Aug 11;152(3):627-36. Epub 2015 Jul 11.

Department of Health Technology and Services Research (HTSR), MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, P.O. Box 217, 7500 AE, Enschede, The Netherlands,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3490-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519578PMC
August 2015

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

Br J Cancer 2015 Jul 16;113(3):396-402. Epub 2015 Jul 16.

1] Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands [2] Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, Utrecht 3584 CG, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2015.256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522644PMC
July 2015

Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial.

J Clin Oncol 2015 Jun 27;33(17):1918-27. Epub 2015 Apr 27.

Hanna van Waart, Martijn M. Stuiver, Wim H. van Harten, Jacobien M. Kieffer, Marianne de Maaker-Berkhof, Gabe S. Sonke, Neil K. Aaronson, The Netherlands Cancer Institute; Edwin Geleijn, Laurien M. Buffart, and Epie Boven, VU University Medical Center; Laurien M. Buffart, EMGO Institute for Health and Care Research; Maud M. Geenen, Sint Lucas Andreas Hospital; Jetske M. Meerum Terwogt, Onze Lieve Vrouwe Gasthuis; Jeanette A.J.H. Hellendoom-van Vreeswijk, Comprehensive Cancer Centre of the Netherlands, Amsterdam; Jolanda Schrama, Spaarne Hospital, Hoofddorp; Aart van Bochove and Simone M. van den Heiligenberg, Esperanz, North Holland; Aart van Bochove, Zaans Medisch Centrum, Zaandam; Vera Lustig, Flevohospital, Almere; Simone M. van den Heiligenberg, Westfries Gasthuis, Hoorn; and Carolien H. Smorenburg, Medical Center Alkmaar, Alkmaar, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.1081DOI Listing
June 2015

Treatment of HER2-positive metastatic breast cancer.

N Engl J Med 2015 05;372(20):1964

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1503446DOI Listing
May 2015

Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.

Ann Surg 2015 Feb;261(2):378-82

Departments of *Surgical Oncology †Pathology ‡Radiology §Medical Oncology; and ¶Statistics, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0000000000000558DOI Listing
February 2015

The facilitating role of chemotherapy in the palliative phase of cancer: qualitative interviews with advanced cancer patients.

PLoS One 2013 6;8(11):e77959. Epub 2013 Nov 6.

Comprehensive Cancer Center The Netherlands, Department of Registry and Research, Utrecht, The Netherlands ; University of Amsterdam, Department of Philosophy, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0077959PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819324PMC
August 2014

Effectiveness of chemotherapy in measurable granulosa cell tumors: a retrospective study and review of literature.

Int J Gynecol Cancer 2014 Mar;24(3):496-505

*Department of Gynecology, Center for Gynecologic Oncology Amsterdam, and †Department of Medical Oncology, Academic Medical Center; and ‡Department of Medical Oncology, Netherlands Cancer Institute, and Department of Research, Comprehensive Cancer Centre Netherlands (IKNL), Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/IGC.0000000000000077DOI Listing
March 2014

Optimising end of life care requires an individualised approach.

BMJ 2014 Mar 25;348:g2312. Epub 2014 Mar 25.

Comprehensive Cancer Centre the Netherlands (IKNL), Rochussentraat 125, 3015 EJ Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmj.g2312DOI Listing
March 2014

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

Breast J 2013 Jul-Aug;19(4):419-26. Epub 2013 May 20.

Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.12124DOI Listing
February 2014

Isolated tumor cells in breast cancer.

N Engl J Med 2009 Nov;361(20):1995; author reply 1995-6

View Article

Download full-text PDF

Source
November 2009

Clinical and therapeutic aspects of extrapulmonary small cell carcinoma.

Cancer Treat Rev 2009 May 9;35(3):228-36. Epub 2008 Dec 9.

Department of Medical Oncology, University Medical Centre Groningen and University of Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2008.10.007DOI Listing
May 2009

A philosophical perspective supports the need for patient-outcome studies in diagnostic test evaluation.

J Clin Epidemiol 2009 Jan 10;62(1):58-61. Epub 2008 Jul 10.

Department of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jclinepi.2008.02.005DOI Listing
January 2009

Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients.

Clin Infect Dis 2008 Jul;47(1):105-8

Departments of 1Medical Oncology and 2Pathology, Antoni van Leeuwenhoek Hospital-Netherlands Cancer Institute, 1006 BE Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/588790DOI Listing
July 2008

Cetuximab for colorectal cancer.

N Engl J Med 2008 Mar;358(11):1196; author reply 1196-7

View Article

Download full-text PDF

Source
March 2008

Prenatal and perinatal risk factors and testicular cancer: a hospital-based case-control study.

Oncol Res 2007 ;16(8):383-7

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3727/000000006783980928DOI Listing
December 2007

A philosophical approach to diagnostic test evaluation.

Ann Intern Med 2007 May;146(10):757; author reply 757-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/0003-4819-146-10-200705150-00015DOI Listing
May 2007

Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.

J Urol 2002 Apr;167(4):1734-9

Department of Urology, University Medical Centre St. Radboud, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00005392-200204000-00035DOI Listing
April 2002

A method for estimating within-patient variability in maximal urinary flow rate adjusted for voided volume.

Urology 2002 Mar;59(3):368-72

Department of Urology, University Medical Center, Nijmegen, The, Nijmegen, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0090-4295(01)01547-3DOI Listing
March 2002